- Home
- EDRY vs IBIO Comparison
EDRY vs IBIO Comparison
Compare EDRY & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | IBIO |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 83.5M |
| IPO Year | 2018 | 2009 |
Fundamental Metrics
Financial Performance| Metric | EDRY | IBIO |
|---|---|---|
| Price | $46.85 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 111.8K | ★ 769.3K |
| Earning Date | 06-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.30 | N/A |
| Revenue Next Year | $10.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.51 | $0.76 |
| 52 Week High | $44.44 | $3.82 |
Technical Indicators
Market Signals| Indicator | EDRY | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 84.55 | 46.96 |
| Support Level | $19.19 | $1.30 |
| Resistance Level | N/A | $1.54 |
| Average True Range (ATR) | 3.07 | 0.07 |
| MACD | 1.14 | 0.01 |
| Stochastic Oscillator | 97.73 | 45.00 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.